Advertisement

Topics

Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)

07:30 EDT 14 Jun 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that positive results from one of the two large Phase 3 studies of ALXN1210, the Company’s investigational long-acting C5 complement inhibitor, in patients with parox...

Other Sources for this Article

Alexion Pharmaceuticals, Inc.
Media
Arne Naeveke, PhD, 475-230-3774
or
Investors
Susan Altschuller, PhD, 475-230-3534

NEXT ARTICLE

More From BioPortfolio on "Alexion Announces Selection of Positive Phase 3 Clinical Data for ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for Late-Breaking Oral Presentation at Annual Conference of the European Hematology Association (EHA)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Diagnostics
A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...